GU Cancers 2025 | Real-world insights into bladder cancer molecular profiling

Alan Tan • 14 Feb 2025

GU Cancers 2025

Alan Tan, MD, Vanderbilt Ingram Cancer Center, Nashville, TN, presents findings on the utility of urinary tumor DNA (utDNA) for real-world bladder cancer monitoring. Similar to plasma circulating tumor (ctDNA), utDNA offers a non-invasive approach for genomic profiling and treatment monitoring, particularly for patients undergoing neoadjuvant chemotherapy or bladder-preserving strategies. By incorporating methylation and whole transcriptome analysis, this evolving assay aims to provide a more comprehensive view or tumor heterogeneity and actionable mutations. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.